FDA - Spark Newswire

3 minute read

FDA
News

Natera Says New Results From Prospective CIRCULATE Trial ‘Expand Clinical Utility Of The Signatera MRD Test In Colorectal Cancer’

Today, 7:50 PM

Natera, Inc. (NASDAQ:NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed molecular residual disease (MRD) assay,

NTRA

3 minute read

BioMarin Announces 12 Presentations At International Society On Thrombosis And Haemostasis (ISTH) 2021 Virtual Congress

By Benzinga Newsdesk

Today, 7:50 PM

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced three oral presentations and nine poster presentations related to valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with

BMRN

1 minute read

FDA
News

Annovis Bio To Present Data At Alzheimer’s Association International Conference 2021 Highlighting Positive Clinical Outcomes from Its 2 Phase 2a Trials

By Benzinga Newsdesk

Today, 7:50 PM

Annovis Bio, Inc. (NYSE:ANVS), ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative

ANVS

1 minute read

FDA
News

AbbVie Publishes Study Titled ‘To Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis’

By Benzinga Newsdesk

Today, 7:50 PM

https://clinicaltrials.gov/ct2/show/NCT04948645

ABBV

1 minute read

FDA
News

Biogen Publishes Trial Titled ‘Exploring Diroximel Fumarate Real-world Experience in Canada and Israel’ To ClinicalTrials.Gov Site

By Benzinga Newsdesk

Today, 7:50 PM

https://clinicaltrials.gov/ct2/show/NCT04948606

BIIB

1 minute read

Arrowhead Stock Drops After RNAi Therapeutic Shows Lung Inflammation In Animal Models

By Vandana Singh

Today, 7:50 PM

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) has voluntarily paused the AROENaC1001 Phase 1/2 study evaluating ARO-ENaC for cystic fibrosis. ARO-ENaC is the company’s…

ARWR

1 minute read

Krystal Biotech’s KB105 Shows Detectable, Functionally Active TGM-1 Enzyme In Genetic Skin Condition

By Vandana Singh

Today, 7:50 PM

Krystal Biotech Inc (NASDAQ:KRYS) announced updated results from the Phase 1/2 trial evaluating topical administration of KB105 in patients with autosomal…

KRYS

1 minute read

Merck To Withdraw Keytruda Accelerated Approval In Third-Line Gastric Cancer Setting

By Vandana Singh

Today, 7:50 PM

On Thursday afternoon, Merck & Co Inc (NYSE:MRK) agreed to withdraw the U.S. accelerated approval indication for third-line gastric cancer indication for…

MRK

4 minute read

The Daily Biotech Pulse: Iterum’s Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures

By Shanthi Rexaline

Today, 7:50 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1)

ALXN

1 minute read

Iterum Stock Nose Dives As FDA Flags Deficiencies In Sulopenem Application

By Vandana Singh

Today, 7:50 PM

â€‹â€‹â€‹â€‹â€‹Iterum Therapeutics plc (NASDAQ:ITRM) has received a letter from the FDA regarding the sulopenem etzadroxil/probenecid marketing application review for uncomplicated urinary…

ITRM